Current Opinion in Oncology was launched in 1989. It is one of a successful series of review journals whose unique format is designed to provide a systematic and critical assessment of the literature as presented in the many primary journals. The field of psychiatry is divided into 15 sections that are reviewed once a year. Each section is assigned a Section Editor, a leading authority in the area, who identifies the most important topics at that time. Here we are pleased to introduce the Journal's Section Editors for this issue.
Cesare Gridelli, MD, is currently Chief of Division of Medical Oncology and Director of Department of Oncology/Hematology at the “S.G. Moscati” Hospital, Avellino, Italy. He earned his medical degree and residencies in Internal Medicine and then in Medical Oncology at the “Federico II” University of Naples, Italy. Since 1993 he has been Vice-Chief of Division of Medical Oncology at the National Cancer Institute of Naples. Coupled with this he has been Chief of the Day Hospital Chemotherapy Unit at the same institute. His areas of expertise are lung cancer and cancer in the elderly. He is deeply involved in the clinical development of new anticancer targeted therapies. He is member of several national (AIOM, AIOT, CTPG) and international scientific societies (ASCO, ESMO,IASLC,ETOP) as well as being a member of the Foundation Council of the European Thoracic Oncology Platform (ETOP). He is a member of the Advisory Board for several scientific journals and for several expert panels. Dr Gridelli has been invited as speaker at international conferences and educational activities of oncology societies. He has authored or co-authored approximately 600 papers, of which 250 are published in international indexed journal, and several book chapters.
Alexander M.M. Eggermont
Alexander M.M. Eggermont, MD, PhD is Professor and Head of the Department of Surgical Oncology at the Erasmus University Medical Center – Daniel den Hoed Cancer Center in Rotterdam, The Netherlands. He also holds the honorary chair of oncology at the Catholique University of Leuven in Belgium. He is a former NCI Surgery Branch Fellow and got his PhD thesis in Tumor Immunology (interferons and cancer). He is a clinical and translational researcher, mostly in the field of melanoma and soft tissue sarcoma. He created the laboratory for experimental surgical oncology together with Timo ten Hagen, which is focused on nano-tools to overcome barriers in tumor pathophysiology, intravital microscopy in innovative tumor models, tumor vasculature and tumor cell motility and metastatic propensity. He is the first president of the European Academy of Cancer Sciences and the past president of ECCO (European CanCer Organization) and the EORTC (European Organization for Research and Treatment of Cancer). He is the past president of the EORTC Melanoma Group and currently chairs the committee of adjuvant strategies in melanoma. He served on the Board of Directors of ASCO and serves on a number of committees of AACR. He is currently Deputy Editor of Clinical Cancer Research and will assume the position of Editor in Chief of the European Journal of Cancer in 2011. He has authored over 500 peer-reviewed scientific publications. He serves on several scientific advisory boards of Scientific Societies, Cancer Institutes and Governments to advise on organizational matters in the field of oncology and research.
Richard J. Jones
Richard J. Jones is Professor of Oncology, Medicine and Pathobiology; Director of the Bone Marrow Transplantation Program, and Co-Director of Hematologic Malignancies at Johns Hopkins University, Baltimore, USA. His major area of interest is normal and malignant stem cell biology, especially the translation of promising findings from the laboratory to the clinic to improve the treatment of malignant and non-malignant blood disorders. He has authored over 200 articles and book chapters on transplantation biology, hematologic malignancies, and hematopoiesis. Dr Jones is a past Stohlman Memorial scholar of the Leukemia and Lymphoma Society.